Poster

Zenocutuzumab, a HER2 × HER3 bispecific antibody, is effective in cancer models with high NRG1 expression

Author

Marie N. O'Connor

Condition

cancer

Drug target

HER2, HER3

Drug moa

Blocking NRG1/HER3 binding and HER2/HER3 dimerization, suppressing tumor cell proliferation and survival via the PI3K-AKT-mTOR pathway

Source url

s3://convoke-optic-posters/2024-05-10/Zeno-poster-AACR2024-FINAL.pdf

3 organizations

1 product

Product

Organization

Organization